iCAD (NASDAQ:ICAD) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of iCAD (NASDAQ:ICAD) from a sell rating to a hold rating in a research note released on Thursday morning.

iCAD Price Performance

ICAD opened at $1.54 on Thursday. The company’s 50-day moving average price is $1.72 and its 200 day moving average price is $1.54. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $2.65. The firm has a market cap of $40.87 million, a price-to-earnings ratio of -11.85 and a beta of 1.47.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Essex LLC acquired a new position in shares of iCAD during the third quarter valued at $216,000. Perritt Capital Management Inc increased its stake in shares of iCAD by 14.2% in the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after purchasing an additional 19,917 shares during the period. Perritt Capital Management Inc. raised its stake in iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after acquiring an additional 9,717 shares in the last quarter. Finally, Virtu Financial LLC lifted its holdings in iCAD by 55.6% in the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock worth $34,000 after purchasing an additional 7,604 shares during the period. Institutional investors and hedge funds own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.